AbbVie Gets FDA OK of Juvmo for Parkinson's Disease

By Colin KellaherAbbVie has won U.S. Food and Drug Administration approval of its Juvmo once-daily oral treatment for the progressive neurological disorder Parkinson's disease.AbbVie on Monday said the green light makes Juvmo (tavapadon) the first and only selective D1/D5 receptor agonist for the t…